COBRA PzF™ Coronary Stent in Clinical and Preclinical Studies: Setting the Stage for New Antithrombotic strategies?

Abstract

Major advances have been made in coronary artery stent technology over the last decades. Drug-eluting stents reduced in-stent restenosis and have shown better outcomes compared with bare metal stents, yet some limitations still exist to their use. Because they delay healing of the vessel wall, longer dual antiplatelet therapy is mandatory to mitigate against stent thrombosis and this limitation is most concerning in subjects at high risk for bleeding. The COBRA PzF nanocoated coronary stent has been associated with accelerated endothelialization relative to drug-eluting stents, reduced inflammation and thromboresistance in preclinical studies, suggesting more flexible dual antiplatelet therapy requirement with potential benefits especially in those at high bleeding risk. Here, we discuss the significance of COBRA PzF in light of recent experimental and clinical studies.

In Vitro Evidence for the Role of Cytokine Storm in the Generation of Stent Thrombosis in COVID-19 Patients

“…The available evidence from this study suggests that the fluoropolymer-coated COBRA stent was associated with the least platelet adhesion and inflammation. In preclinical studies, COBRA PzF nanocoated stents were associated with accelerated endothelialization, and lower inflammation and thromboresistance, further supporting the current results of lower platelet adhesion and inflammation [12] . Thus, the current provocative in vitro study results indicate that the nanocoated COBRA-PzF may provide the maximum benefit of reduced thrombogenicity in COVID-19 patients.…”

Evaluation of the safety and efficacy of a Polyzene-F nanocoated coronary stent system: A systematic review and single-arm meta-analysis

“…The nanolayer PzF exhibits superior properties such as thromboresistance ( 20 ), confirmed by preclinical studies during follow-ups ( 9 ). Thus, Cobra PzF was approved in 2017 ( 7 ).…”

“…This problem resulted in the development of the Cobra Polyzene-F (PzF) coronary stent (CeloNova BioSiences, San Antonio, TX, USA) ( 4 ) and Catania PzF coronary stent (CeloNova Biosciences, Newnan, GA, USA) ( 5 ), both of which were designed to address the shortcomings of the DES, especially to decrease ST occurrence. Preclinical studies have shown that these PzF-nanocoated stents exhibited thrombo-resistant, anti-inflammatory, and rapid healing properties in endothelialization ( 6 , 7 ), and the Cobra PzF stent in a preclinical study suggested a flexible DAPT requirement with potential benefits, especially in patients with high bleeding risk ( 7 ). However, whether these two kinds of stents showed consistent efficacy in clinical use was still unclear.…”